Insulet (NASDAQ:PODD) Stock Price Down 3.4% Following Analyst Downgrade

Key Points

• Insulet Corporation shares dropped 3.4% following a downgrade by The Goldman Sachs Group, which reduced the price target from $399 to $375, although still maintaining a buy rating.
• Analyst consensus is currently a Moderate Buy with a target price of $345.47, while multiple analysts, including JPMorgan and Oppenheimer, have issued positive price adjustments.
• Insider selling activity included significant transactions, with two senior vice presidents reducing their positions, reflecting a 17% and 16.58% decrease respectively.

Insulet Corporation (NASDAQ:PODD - Get Free Report)'s share price was down 3.4% during mid-day trading on Wednesday after The Goldman Sachs Group lowered their price target on the stock from $399.00 to $375.00. The Goldman Sachs Group currently has a buy rating on the stock. Insulet traded as low as $305.22 and last traded at $298.14. Approximately 50,130 shares changed hands during trading, a decline of 93% from the average daily volume of 742,312 shares. The stock had previously closed at $308.73.

A number of other analysts have also recently issued reports on the company. Jefferies Financial Group reissued a "buy" rating on shares of Insulet in a research report on Thursday, August 7th. JPMorgan Chase & Co. increased their target price on shares of Insulet from $340.00 to $415.00 and gave the stock an "overweight" rating in a research note on Friday, September 12th. Barclays upped their price objective on Insulet from $266.00 to $300.00 and gave the company an "equal weight" rating in a research note on Thursday, August 21st. Wall Street Zen raised Insulet from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Finally, Oppenheimer increased their price target on Insulet from $324.00 to $365.00 and gave the stock an "outperform" rating in a report on Monday, September 8th. Sixteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $345.47.

Insider Buying and Selling at Insulet

In related news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares in the company, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president owned 3,456 shares of the company's stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.39% of the company's stock.

Institutional Trading of Insulet

Hedge funds have recently bought and sold shares of the company. Inspire Investing LLC lifted its stake in shares of Insulet by 299.5% during the 1st quarter. Inspire Investing LLC now owns 4,119 shares of the medical instruments supplier's stock worth $1,082,000 after purchasing an additional 3,088 shares during the period. Allspring Global Investments Holdings LLC boosted its position in shares of Insulet by 55.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 5,229 shares of the medical instruments supplier's stock worth $1,376,000 after acquiring an additional 1,867 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Insulet by 1.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 579,302 shares of the medical instruments supplier's stock valued at $152,130,000 after purchasing an additional 10,628 shares during the last quarter. Gradient Investments LLC purchased a new stake in shares of Insulet during the 2nd quarter valued at $17,429,000. Finally, Vident Advisory LLC acquired a new stake in shares of Insulet during the 1st quarter worth $216,000.

Insulet Stock Down 5.9%

The firm has a market capitalization of $20.45 billion, a PE ratio of 88.85, a price-to-earnings-growth ratio of 2.58 and a beta of 1.36. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The firm has a 50-day moving average of $320.07 and a two-hundred day moving average of $297.80.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. During the same period in the previous year, the company posted $0.55 EPS. The company's revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities research analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.